Login to Your Account



AASLD Roundup


Wednesday, November 9, 2011
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said results from the SILEN-C3 Phase IIb study showed the potential for BI201335, its next-generation protease inhibitor, in combination with pegylated interferon and ribavirin, to shorten treatment duration to 12 weeks and to improve the likelihood of viral cure compared to the former traditional standard of care – pegylated interferon and ribavirin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription